Biocon has launched advanced novel therapy for the treatment of Hepatitis C at a lower price.
CIMIVIR-L, a fixed dose combination of Ledipasvir 90 mg and Sofosbuvir 400 mg, will be made available to Indian patients at a fraction of the global cost of the innovator brand, said Biocon Ltd in its statement.
A 12-week course of the combination therapy in the US will cost US$ 94,500 (about Rs 63 lakh).
According to Ravi Limaye, President-Marketing, Biocon, the introduction of CIMIVIR-LTM will strengthen the company’s present portfolio of virology products. It will further Biocon’s commitment to offering affordable therapy for unmet patient needs in debilitating and life-threatening conditions.
CIMIVIR-L is an equivalent of the innovator product commercialised by Gilead Sciences in the US.
Biocon last year had entered into a licensing agreement with Gilead to manufacture and commercialise its chronic Hepatitis-C blockbuster product range, Sofosbuvir and Sofosbuvir-Ledipasvir combination in India and in selective emerging markets.
The Drugs Controller General of India (DCGI) had recently approved the sale of Sofosbuvir-Ledipasvir combination, which is being manufactured in India under a license from Gilead.
CIMIVIR-L will offer a convenient, effective and safe alternative to people infected with the Hepatitis-C virus. It is indicated for Hepatitis-C Genotype 1 patients who account for 25 per cent of the total estimated HCV patient population of 18 million in the country.